NewLink Genetics (NLNK) Tops Q1 EPS by 88c

NewLink Genetics (NASDAQ: NLNK) reported Q1 EPS of ($0.82), $0.88 better than the analyst estimate of ($1.70). Revenue for the quarter came in at $4.34 million versus the consensus estimate of $2.08 million.

NewLink Genetics ended the quarter on March 31, 2016, with cash, cash equivalents, and certificates of deposit totaling $178 million compared to $197.8 million for the year ending December 31, 2015. The decrease was attributable primarily due to the increased operating expenses for R&D and pre-commercialization development, offset by amounts received under government contracts.

For earnings history and earnings-related data on NewLink Genetics (NLNK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Movano (MOVE) Misses Q2 EPS by 195c